Scotch Plains, NJ, United States of America

Jack D Scott

USPTO Granted Patents = 45 (Patent Applications = 7)

CIPO Patents = 1

EPO Patents = 33 (Patent Applications = 33)

Average Co-Inventor Count = 4.3

ph-index = 8

Forward Citations = 179(Granted Patents)

Location History:

Twin Falls, ID (US) (1980)
Springfield, NJ (US) (2007 - 2008)
Scotch Plains, NJ (US) (2010 - 2021)

Company Filing History:

35 out of 2,405

Merck Sharp + Dohme Corp.

Intervet International B.v.

patents

5. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1980-2021

Loading Chart...

45 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11207312 - Metallo-beta-lactamase inhibitors and methods of use thereof (2021-12-28),

2. 10954240 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2021-03-23),

3. 10544130 - Metallo-beta-lactamase inhibitors (2020-01-28),

4. 10329291 - C5-C6-carbocyclic fused iminothiadiazine dioxides as BACE inhibitors, compositions, and their use (2019-06-25),

5. 10238743 - C5-C6-fused tricyclic iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use (2019-03-26),

6. 10227331 - Metallo-β-lactamase inhibitors (2019-03-12),

7. 10221163 - Metallo-beta-lactamase inhibitors (2019-03-05),

8. 10047098 - C5-C6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use (2018-08-14),

9. 9957269 - S-imino-S-oxo iminothiazine compounds as bace inhibitors, compositions, and their use (2018-05-01),

10. 9802928 - C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors, compositions, and their use (2017-10-31),

11. 9745324 - Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use (2017-08-29),

12. 9725468 - C5-spiro iminothiazine dioxides as BACE inhibitors, compositions, and their use (2017-08-08),

13. 9718818 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2017-08-01),

14. 9688654 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2017-06-27),

15. 9687494 - Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use (2017-06-27),

Title: The Innovative Journey of Jack D Scott: Pioneering Inventions in Pharmaceutical Sciences

Introduction:

Jack D Scott, a distinguished inventor based in Scotch Plains, NJ, has made significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 45 patents, his groundbreaking work in developing Metallo-β-lactamase inhibitors and compounds inhibiting leucine-rich repeat kinase enzyme activity has revolutionized the landscape of antibiotic resistance and disease treatment.

Latest Patents:

1. Metallo-β-lactamase Inhibitors and Methods of Use Thereof: Jack D Scott's invention focuses on metallo-β-lactamase inhibitor compounds that are crucial in overcoming antibiotic resistance. This innovative approach not only entails the synthesis of these compounds but also their effective utilization in combination with β-lactam antibiotics and beta-lactamase inhibitors to combat bacterial infections.

2. Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity: In his latest patent, Jack D Scott introduces substituted reversed indazole compounds as potent inhibitors of LRRK2 kinase. These compounds exhibit immense potential in treating diseases such as Parkinson's Disease, where LRRK2 kinase plays a pivotal role. The patent also encompasses the formulation of pharmaceutical compositions for the prevention and treatment of these diseases.

Career Highlights:

Jack D Scott has honed his expertise through collaborations with renowned pharmaceutical companies such as Merck Sharp & Dohme Corporation and Schering Corporation. His tenure in these esteemed organizations has been marked by relentless innovation and a commitment to translating scientific discoveries into tangible solutions for global healthcare challenges.

Collaborations:

During his professional journey, Jack D Scott has had the privilege of working alongside esteemed colleagues like Jared N Cumming and Andrew William Stamford. These collaborative efforts have played a crucial role in advancing the frontiers of pharmaceutical research and development, paving the way for novel therapeutic interventions.

Conclusion:

In conclusion, Jack D Scott stands as a beacon of ingenuity in the realms of pharmaceutical inventions. His unwavering dedication to addressing antibiotic resistance and neurodegenerative diseases through pioneering patents underscores his profound impact on the healthcare landscape. With an illustrious career marked by innovation and collaboration, Jack D Scott continues to inspire future generations of inventors in the pursuit of transformative scientific breakthroughs.

This text is generated by artificial intelligence and may not be accurate.